Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
May 24, 2026, 04:57Ahmed Elsobky: Strengthening Hemophilia Care Under Egypt’s Universal Health Insurance System
-
May 24, 2026, 04:49Hussien Hishmat: There Is More to Pulmonary Embolism than Just Anticoagulation
-
May 24, 2026, 04:25Sarah Elkourashy: Diagnostic Challenges and Management Strategies for Maternal–Fetal Outcomes in TTP
-
May 24, 2026, 04:11Ayah Ghazi Al-Qasrawi: How Should Sepsis-Induced DIC Be Managed in Patients Receiving Thienopyridines
-
May 24, 2026, 04:05Kate Hayward: Recent Stroke Recovery and Rehabilitation Highlights
-
May 24, 2026, 03:33Raghavendra Rao: Short-Term Outcomes of Combined EVLA and Foam Sclerotherapy
-
May 24, 2026, 03:33Lucia Mazzolai: Systemic Vascular Approach to Peripheral Artery Disease
-
May 24, 2026, 03:32Isaac Okello: Africa CDC Launches Continental Framework for Sickle Cell Disease
-
May 24, 2026, 03:32Karine Kocharian: Advancing Hemophilia Care Equity at the 79th World Health Assembly